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Cholinesterase inhibitors constitute one of the mainstays of treatment of
Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing
therapeutic doses and poor patient compliance have been identified as barriers
to effective treatment with these substances. The rivastigmine transdermal
patch provides continuous delivery of drug through the skin into the
bloodstream, avoiding the fluctuations in plasma concentration associated with
oral administration. This pharmacokinetic profile is associated with reduced
side effects, resulting in easier access to expected target doses. These benefits,
along with other practical advantages of the transdermal patch, may contribute
to enhanced patient compliance. Here, we present a review of the current
literature on rivastigmine patch, and offer advice based on our own collective
clinical experience. Rivastigmine patch provides an efficient option for
managing patients with AD, to be considered among the first line therapies
for the disease.
Introduction
Conventionally, treatments for the management of
Alzheimer’s disease (AD) have all been adminis-
tered orally. Cholinesterase inhibitors, exemplified by
donepezil, galantamine, and rivastigmine, form one of
the mainstays of AD treatment and have been available
since 1997. The N-methyl D-aspartate (NMDA)-receptor
antagonist memantine followed in 2006. Oral rivastig-
mine (capsules or liquid) was also approved in many
countries worldwide for the treatment of mild to
moderate Parkinson’s disease dementia (PDD) in 2006.
Alzheimer’s disease is a progressive neurodegenerative
condition that predominantly affects the elderly
population; as such the management of the disease
poses challenges to both the patient and their caregiver.
There can be a high medication burden due to concurrent
illnesses [1]. The use of multiple drugs every day places
AD patients at a greater risk for poor compliance, hence
effective and well-tolerated treatment options that might
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enhance compliance are welcome [2]. Transdermal
patch therapy has the potential to reduce the side effects
observed with orally administered drugs allowing easier
access to optimal doses and easier administration, bene-
fits which are expected to enhance patient compliance.
Rivastigmine is a cholinesterase inhibitor that inhibits
both acetylcholinesterase (AChE) and butyryl-
cholinesterase (BuChE) [3]. The efficacy of oral
rivastigmine has been demonstrated in pivotal clini-
cal trials involving more than 3000 AD patients and 500
PDD patients [4–8]. Rivastigmine is a small molecule
(<400 Da), and is both lipophilic and hydrophilic [9].
These properties mean that rivastigmine can pass easily
through the skin into the bloodstream as well as
through the blood–brain barrier, making it well-suited to
transdermal delivery. Its high potency is also advanta-
geous since it allows a transdermal patch to be small and
discreet [9]. These properties, combined with improved
patch technology, constituted the basis for the develop-
ment of rivastigmine transdermal patch, the first trans-
dermal option for the symptomatic treatment of mild to
moderate AD [10]. Several primary papers have been
published demonstrating the pharmacokinetic profile,
efficacy, and safety of rivastigmine capsules and patch.
The objective of this article is to provide primary care
physicians, specialists, and other professionals working
in the field with a concise and comprehensive review of
the rivastigmine transdermal patch for treatment of AD.
Rationale for Transdermal Patch
Treatment in Dementia
Cholinesterase inhibitors are associated with central
cholinergic gastrointestinal side effects, such as nau-
sea and vomiting, particularly during initial dose titra-
tion [11,12]. This is believed to be caused by the rapid
increase in acetylcholine levels in the brain resulting
from inhibition of the target enzyme(s) [13]. Strategies
that prolong the time to reach maximal drug plasma
concentrations have been shown to reduce the incidence
of gastrointestinal side effects with cholinesterase in-
hibitors, in particular with rivastigmine. For example,
administering rivastigmine with food reduces gastroin-
testinal side effects by delaying absorption from the
gastrointestinal tract [14]. Further, in a 26-week
placebo-controlled study in which rivastigmine capsules
were administered twice daily (BID) or three times
daily (TID) in 687 mild to moderate AD patients,
the TID dosing regimen was shown to be superior in
terms of tolerability [7]. These findings indicated that
a more gradual increase in plasma concentration that
prolongs the time to reach maximal values, would be
expected to lead to reduced side effects. In turn, this
would allow easier access to optimal doses, improving
patient compliance and potentially efficacy. Transder-
mal administration delivers a drug directly through the
skin into the bloodstream, avoiding the gastrointesti-
nal tract, thus avoiding the first-pass effect as well as
potential interaction with other drugs with regards to
absorption. Smooth delivery is also expected to provide
a steadier plasma concentration of the drug.
Along with an improved pharmacokinetic profile lead-
ing to improved tolerability, transdermal drug delivery
may offer other practical benefits. Some AD patients
have been shown to exhibit “non-responsiveness” to
cholinesterase inhibitors. It has been proposed that this
may be due to genetic factors, ultra-rapid metabolism
or progressive damage to cholinergic neurons; in some
cases, however, it may be due to under-dosing and poor
compliance [15]. The simplified dosing regimen provided
by a transdermal patch has the potential to improve
compliance and provide access to higher doses, particu-
larly for those patients who already have a high med-
ication burden [1]. A transdermal patch also provides
visual reassurance to the caregiver that medication is
being taken, as well as reducing the risk of accidental
over-dosing. There is an additional advantage for patients
that have swallowing difficulties.
Pharmacokinetic Profile of the
Rivastigmine Patch
The pharmacokinetic profile of the rivastigmine patch
was compared to that of the rivastigmine capsule in
an open-label, ascending dose study of 51 AD patients
[16]. Rivastigmine capsule was rapidly absorbed, with
a median tmax of 1 h for all doses. In comparison, tmax
with rivastigmine patch was reached at approximately
8 h for all patch sizes, reflecting the more gradual
increase in plasma concentration with transdermal
administration. The mean Cmax with transdermal
administration was consistently lower than with capsules,
and there was less variation in peak–trough rivastigmine
concentrations, demonstrating a smoother, continuous
drug delivery [16].
Drug exposure, assessed by measuring the area under
the curve, showed that the starting dose 4.6 mg/24 h
patch provided comparable drug exposure to 6 mg/day
capsules, while the target dose 9.5 mg/24 h patch pro-
vided comparable exposure to the highest recommended
dose of capsules, 12 mg/day (Figure 1) [17,18]. The effi-
cacy of rivastigmine is dose-dependent, but a 6 mg/day
dose of rivastigmine capsules has been shown to
provide therapeutic drug levels [19]. As the 4.6 mg/24 h
patch provides comparable drug exposure to 6 mg/day
capsules, transdermal administration of rivastigmine is
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Figure 1 Mean plasma rivastigmine levels following administration of 9.5 mg/24 h patch versus 12 mg/day capsules (adjusted for baseline weight and
gender) [17]. Reproduced from Expert Rev Neurotherapeutics 2007;7:1457–1463 with permission from Expert Reviews Ltd [18].
expected to provide plasma concentrations within the
range of effective therapeutic doses from the initiation of
treatment.
The pharmacokinetic study was also designed to com-
pare inhibition of target enzymes with the rivastigmine
patch and capsule [16]. AChE has an extremely low
concentration in the plasma, and as such the enzymatic
activity is hard to measure. However, as rivastigmine
is a dual inhibitor, the enzymatic activity of BuChE in
the plasma may be used as a marker of target enzyme
inhibition over time [20,21]. The pharmacodynamics of
rivastigmine mirrored the pharmacokinetic profile, with
the transdermal patch providing a smooth, continuous
reduction in plasma BuChE activity, while two distinct
peak–troughs were seen with capsule administration.
A separate study examined the effect of body
application site on the pharmacokinetics of rivastigmine
patch, and showed that bioavailability was greatest when
the patch was applied to the upper back, upper arm, or
chest [22]. Adhesiveness was also good at these body
sites. The patch may be applied to one of these sites to
ensure maximal exposure, although application site rota-
tion (including alternating between left and right sides of
the body each day) is an important strategy in optimizing
skin tolerability with medical patches.
In order to provide the concentration gradient required
to drive the diffusion of rivastigmine through the skin,
all rivastigmine transdermal patches are loaded with a
greater amount of the drug than will be absorbed into
the bloodstream. The average amount of rivastigmine
absorbed from a patch over a 24-h application period
is approximately 50% of the total loading dose [16].
Absorption of any remaining rivastigmine following the
24-h application period occurs very slowly. Although
the previous patch should be removed before the new
one is administered, patients are at a low risk of toxic
exposure should a new patch be mistakenly applied
without prior removal of the previous patch [23]. Once
the patch is removed, the short elimination half-life of
rivastigmine (∼3.4 h) ensures a rapid reduction of drug
levels in the plasma [16]. As a result, even with the
continuous delivery provided by the rivastigmine patch,
there is little potential for drug accumulation in the body.
This can also be an advantage under emergency condi-
tions when a rapid removal of the cholinergic drug is
desired.
Efficacy and Safety of the Rivastigmine
Patch
The efficacy and safety of the rivastigmine patch was
evaluated in a single, 24-week, international, random-
ized, double-blind trial of 1,195 patients with mild to
moderate AD [10]. The Investigation of transDermal
Exelon in ALzheimer’s disease (IDEAL) study enrolled
patients with probable AD (Mini-Mental State Exam-
ination [MMSE] scores of 10–20). Patients were ran-
domized to placebo, rivastigmine capsule (12 mg/day),
rivastigmine 9.5 mg/24 h patch or rivastigmine 17.4 mg/
24 h patch. They were titrated to their target doses
in 4-week intervals over 16 weeks and maintained at
their highest well-tolerated dose for the remaining 8
weeks. Primary outcome measures were the Alzheimer’s
Disease Assessment Scale-Cognitive subscale (ADAS-
cog), and the Alzheimer’s Disease Cooperative Study-
Clinical Global Impression of Change (ADCS-CGIC).
Secondary efficacy outcomes included the Alzheimer’s
Disease Cooperative Study-Activities of Daily Living
(ADCS-ADL), the MMSE, the Neuropsychiatric Inven-
tory (NPI), and the Trail-making Test part A (TMT-A).
With regard to the drug exposure, although the target
dose in the capsule group was 12 mg/day, the mean oral
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Table 1 Mean changes from baseline at Week 24 for primary and
secondaryefficacymeasures in the IDEALstudy (ITT-LOCFpopulation) [10].
Reproduced from Expert Rev Neurotherapeutics 2007;7:1457–63 with
permission from Expert Reviews Ltd. [18]
Mean 24-week change from baseline
Rivastigmine Rivastigmine Placebo
9.5 mg/24 h patch12 mg/day capsules
Primary measures
ADAS-cog −0.6∗∗ −0.6∗∗ 1.0
ADCS-CGIC 3.9∗∗ 3.9∗∗ 4.2
Secondary measures
MMSE 1.1∗∗ 0.8∗∗ 0.0
Trail Making Test part A −12.3∗∗∗ −9.8∗∗∗ 7.7
ADCS-ADL −0.1∗∗ −0.5∗ −2.3
NPI-12 −1.7 −2.2 −1.7
ADAS-cog, cognitive subscale of the Alzheimer’s Disease Assessment
Scale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of
Daily Living scale;ADCS-CGIC,Alzheimer’sDiseaseCooperative StudyClin-
ical Global Impression of Change; MMSE, Mini-Mental State Examination;
NPI-12, 12-item Neuropsychiatric Inventory.
Negative change scores onADAS-cog, TrailMaking Test part A, andNPI-12
indicate improvement.
Negative change scores on MMSE and ADCS-ADL indicate deterioration.
ADCS-CGIC is scored as a judgement of change,with a score of 4 indicating
no change,<4 indicating improvement, and>4 indicating deterioration.
∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001 versus placebo.
dose was 9.7 mg/day, with 64.4% of patients achieving
the maximal 12 mg/day. In contrast, the mean patch size
applied to patients in the 9.5 mg/24 h (10 cm2) patch
group was 9.8 cm2, with almost all patients (95.9%)
reaching the target 9.5 mg/24 h patch [10,23].
All rivastigmine treatment groups (patch and capsule)
showed significant improvements compared with placebo
at Week 24 with respect to the primary outcomes (ADAS-
cog, ADCS-CGIC), as well as many of the secondary
outcomes (ADCS-ADL, MMSE, TMT-A) (Table 1) [10].
The 9.5 mg/24 h patch provided similar efficacy to cap-
sules (maximum 12 mg/day) on these outcome mea-
sures.
The most striking findings comparing oral capsules
with transdermal patch were observed with regards
to adverse events. The most commonly reported ad-
verse events in the IDEAL study tended to be those
associated with cholinergic overstimulation in general,
including gastrointestinal events, such as nausea, vomit-
ing, and diarrhoea [10]; these were mostly classed as mild
or moderate. In the 9.5 mg/24 h patch treatment group,
7% and 6% of patients experienced nausea and vomiting,
respectively, compared with 23% and 17% of patients
receiving capsule. The incidence of nausea and vomit-
ing in the 9.5 mg/24 h rivastigmine patch group was
not significantly different to that observed with placebo.
Weight loss was less frequent in patch-treated patients
compared with those who received capsule (3% in the
9.5 mg/24 h patch group, 5% in the capsule group,
and 1% in the placebo group experienced a decrease in
weight during the 24-week study).
The majority of patients experienced no, mild, or mod-
erate application site skin reactions, and the incidence
of severe skin reactions was low. In total, 7.6% of pa-
tients reported moderate or severe erythema with the
9.5 mg/24 h patch, and less than 2.5% of patients dis-
continued due to adverse skin reactions [10].
Switching to the Rivastigmine Patch
During an open-label extension of the IDEAL study,
in which all patients who entered the extension phase
were switched to the 9.5 mg/24 h patch without titra-
tion, rivastigmine patch displayed a similar safety and
tolerability profile; treatment effects were largely sus-
tained for up to 1 year [24]. Similar to the double-blind
phase, adverse events were predominantly cholinergic in
nature and mild to moderate in severity, with nausea
and vomiting reported most frequently. A relevant find-
ing was that patients formerly randomized to rivastig-
mine treatment (capsule or patch) reported fewer adverse
events than those formerly randomized to placebo, indi-
cating that treatment with rivastigmine patch should be
started with the lower patch size in patients who have not
been previously exposed to rivastigmine [24].
The SWitch from Aricept to Patch (SWAP) study was
a prospective, 5-week, open-label, randomized, paral-
lel group study that evaluated the safety and toler-
ability of switching from 5 to 10 mg/day donepezil
tablets to rivastigmine transdermal patch [25]. Patients
were randomized to two groups: those who switched to
rivastigmine 4.6 mg/24 h patch immediately, and those
who discontinued donepezil treatment 7 days before ini-
tiation of patch therapy. In both groups, rivastigmine
patch was well-tolerated, with a low incidence of nau-
sea (<4% in both groups) and vomiting (<2% in both
groups). There were no statistically significant differences
between the switch paradigm groups with regards to ad-
verse events or to the number of patient discontinuations
[25].
Based on these two studies [24,25], guidelines for
switching patients already receiving oral cholinesterase
inhibitors to rivastigmine patch have been developed.
New (treatment-naı¨ve) patients should receive the
4.6 mg/24 h patch for 4 weeks and then, tolerability per-
mitting, be titrated to the 9.5 mg/24 h patch. Patients
taking ≤6 mg/day rivastigmine orally should switch to
the 4.6 mg/24 h patch before titrating to the target dose
after 4 weeks. Patients taking >6 mg/day rivastigmine
CNS Neuroscience & Therapeutics 16 (2010) 246–253 c© 2010 Blackwell Publishing Ltd 249
Transdermal Rivastigmine Patch in AD M. Emre et al.
orally may switch directly to 9.5 mg/24 h patch, unless
an oral dose of 9 mg/day has not been stable or well-
tolerated, in which case a switch to the 4.6 mg/24 h patch
is recommended. These recommendations are based on
EU guidelines [26]; regional differences may apply. For
example, in the USA, it is recommended that patients re-
ceiving an oral dose of less than 6 mg/day are switched
to the 4.6 mg/24 h patch, while all patients receiving 6
mg/day or more can be switched directly to the 9.5 mg/24
h patch [27].
Based on our clinical experience, a perceptible loss
of efficacy may be observed by caregivers in patients
who are switched from the 12 mg/day oral doses to
the 4.6 mg/24 h patch, and vice versa, an intolerable
“excessive” effect with hyperactivity, restlessness and ir-
ritability may appear if patients on oral doses of less than
6 mg/day are put directly on the 9.5 mg/24 h patch.
Patients with AD receiving donepezil tablets may also
switch directly to rivastigmine 4.6 mg/24 h patch with-
out a withdrawal period. The first patch should be ap-
plied the day after the last oral dose. To date, no clinical
studies evaluating the safety and tolerability of switch-
ing patients from galantamine to the rivastigmine patch
have been published in the primary literature. The choice
of patch size to be initially used in patients previously
receiving galantamine is therefore based on physician’s
discretion.
Similarly, there are currently no data available on the
use of rivastigmine patch in combination with meman-
tine. However, studies with rivastigmine capsule and me-
mantine in patients with AD did not detect any safety
issues with combination therapy [28–30]. Our clinical ex-
perience suggests that combination therapy with rivastig-
mine patch and memantine is tolerable and may provide
added benefits.
Clinical Utility of Rivastigmine Patch
The rivastigmine patch is applied once-daily. It is
important to ensure that the caregiver is aware that the
old patch should be removed before a new patch is ap-
plied. Caregivers can write on the rivastigmine patch to
serve as a reminder, if necessary. Some caregivers write
the day of the week onto the patch so that they can be
sure that they have applied the patch that day and re-
moved the previous day’s patch. Everyday activities, such
as bathing, showering, and swimming, can be continued.
When the 24-h period is over, the patch should be re-
moved gently (“ripping”off the patch should be avoided,
as this can damage fragile skin). Any residual patch adhe-
sive can be removed using an oil-based substance such as
olive oil or baby oil.
The rivastigmine patch should be applied to gently
cleaned, dry, hairless, intact, healthy skin. Recommended
application sites are the upper or lower back, chest, or
upper arm. It is important to rotate the application site
daily (alternating between left and right sides of the
body); if possible, the same exact area should not be used
again for at least 14 days. This simple rotation of the ap-
plication site can result in better skin tolerability [27].
When using the patch, some patients may develop
skin reactions. These typically take the form of erythema
(redness) and pruritus (itching), caused by irritation,
and usually do not present a serious medical problem.
Nevertheless, simple steps may be taken to minimize
these events and enhance patient comfort. Other than
rotation of the application site, additional precautions
include keeping skin healthy by moisturizing (particu-
larly for elderly patients who tend to have dry, fragile
skin), and trimming rather than shaving excess hair at
the application site. Should irritation occur, moisturizers
may help speed the healing of secondary symptoms such
as scaling [31], and antihistamines or zinc oxide/iron
(III) oxide suspension can relieve troublesome itching.
Allergic dermatitis with rivastigmine patch is rare, and
typically manifests as localized redness with swelling,
which may “spread” beyond the border of the patch. Top-
ical corticosteroids may be used in cases of severe allergic
dermatitis. If the signs and symptoms of dermatitis are
not tolerable by the patient at any point, patch treatment
should be discontinued. Appropriate management and
treatment will help to ensure that any signs and symp-
toms of skin reactions, should they occur, will likely be
transient, mild-to-moderate, and cause minimal discom-
fort. If skin reactions remain, but the patient and care-
giver are satisfied with patch treatment, we recommend
consulting a dermatologist for advice on overcoming the
skin tolerability problems.
Adhesion of the patch to the skin is very good, with
caregivers in the IDEAL study reporting that the patch
was completely attached or had the edges just lifting
off in 96% of the 1,336 adhesion evaluations of the
9.5 mg/24 h patch. This was despite normal activities such
as bathing being allowed, and some study centres being
located in warm climates where perspiration would be
expected [10].
Caregiver preference for patches versus capsules was
a prospective outcome measure in the IDEAL study.
The results showed that more than 70% of caregivers
preferred patches to capsules overall. Patches were pre-
ferred to capsules with respect to ease of use and
ease of following the schedule, and caregivers indicated
greater satisfaction with patch therapy overall, and less
interference with daily life [32]. Improved caregiver
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Table 2 Practical tips and comments on utility of rivastigmine patch, based on clinical experience
• May help to improve patient compliance; may be ideal for patients who already have high medication burdens or swallowing problems.
• May reduce caregiver stress as caregivers indicated reduced interference with daily life and greater overall satisfaction.
• Skin reactions may occur; irritant reactions account for the majority of cases, and are generally harmless and manageable.
• The risk of skin irritation can be minimized by:
◦ rotating the application site daily
◦ removing the patch gently (avoiding “ripping”)
◦ removing residual adhesive with oil-based substances such as olive oil
◦ keeping skin healthy by moisturizing
◦ trimming rather than shaving any hair at the application site.
• Should irritation occur, moisturizer can be used to speed healing, antihistamines, or ointments can relieve troublesome itching.
• Ensure that there are no misunderstandings regarding application sites; only one site should be used at a time. Do not cut the patch. The old patch
should be removed before a new patch is applied, and the old one should be properly disposed of as it still contains active substance.
satisfaction may be expected to lead to better compliance
to treatment.
The rivastigmine patch was first approved for the
treatment of mild to moderate AD in Europe in 2007.
Our clinical experience with the rivastigmine patch sup-
ports findings from the clinical studies, confirming that
the patch is an effective and valuable treatment option
for AD patients. Based on our own cumulative clinical
experience, some practical advice and suggestions for
physicians prescribing the rivastigmine patch to their pa-
tients, and some potential additional features of the patch
that we have observed in our clinics, are listed in Table 2.
Conclusions
Cholinesterase inhibitors are commonly used to treat
the symptoms of AD. However, poor patient compli-
ance due to gastrointestinal side effects and difficulty ac-
cessing therapeutic doses with oral administration can
be a barrier to effective therapy [1]. Although patients
typically have AD for more than 7 years [33], studies
have shown that the average treatment duration with the
oral cholinesterase inhibitors rivastigmine and donepezil
ranges from about 120 to 500 days [34–36]. The ad-
vantages of continuing cholinesterase inhibitor therapy
should not be underestimated; patients who manage to
stay on therapy for longer have a greater chance of slow-
ing or delaying progression of their symptoms, and a de-
creased risk of institutionalization [37,38].
The pharmacokinetic profile of the rivastigmine
transdermal patch reduces side effects, allowing patients
to more easily reach target doses and to stay on treat-
ment for longer [10,23]. These benefits, along with the
simplified drug regimen, visual reassurance of drug ad-
ministration and other practical advantages provided by
the patch, give transdermal administration the potential
to improve treatment compliance in AD. Elderly people
may derive particular benefit from transdermal drug ad-
ministration for a number of reasons. Elderly patients of-
ten have a high medication burden, and have to take a
number of drugs for different conditions every day. This
can lead to poor compliance due to forgetfulness and con-
fusion caused by complicated drug regimens [1]. In addi-
tion, a greater number of comorbidities, and difficulties
in swallowing, mean that the elderly should be consid-
ered as a group with special requirements with regards
to drug administration [39]. Transdermal administration
of rivastigmine may be an age-appropriate way to deliver
this drug to elderly patients [40].
Cholinesterase inhibitors and memantine are the only
currently available treatments for AD. Although these
therapies effectively relieve the symptoms of AD, they
have a limited effect on the progression of the disease. It
is hoped that in the future, development of therapies that
directly target the underlying pathology of AD may offer
more substantial disease modification. Combinations of
these novel disease-modifying agents with symptomatic
treatments like cholinesterase inhibitors may become the
standard therapeutic regimen for patients with AD.
In summary, rivastigmine patch provides an efficient
option for managing patients with AD, and should be
considered a first-line therapy for mild to moderate AD
patients. In the USA, the patch is also approved for
patients with PDD, based on the bioequivalence data
of rivastigmine patches versus capsules and the proven
effect of rivastigmine itself in PDD patients. A study with
the rivastigmine patch in patients with PDD is ongoing,
primarily focusing on safety.
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